Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines
Open Access
- 1 January 2015
- journal article
- Published by Korean Breast Cancer Society in Journal of Breast Cancer
- Vol. 18 (4) , 329-338
Abstract
Ávila-Arroyo S, et al. J Breast Cancer. 2015 Dec;18(4):329-338. http://dx.doi.org/10.4048/jbc.2015.18.4.329Keywords
This publication has 29 references indexed in Scilit:
- Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)International Journal of Cancer, 2013
- Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cellsBreast Cancer Research and Treatment, 2012
- MRE11Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal CancersCancer Research, 2011
- CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP InhibitorsCancer Research, 2011
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and CisplatinCancer Research, 2010
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- PARP inhibitors: New partners in the therapy of cancer and inflammatory diseasesFree Radical Biology and Medicine, 2009
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivityDNA Repair, 2008
- Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743Proceedings of the National Academy of Sciences, 2007
- BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious MutantsCancer Research, 2006